Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium adenosine nucleonate (Adenorine) is an immunostimulating agent being evaluated by the MIPO Clinic as an adjunctive mitochondrial immunotherapy for patients with metastatic colorectal cancer. It functions by activating the monocyte-macrophage system, enhancing cellular repair and regeneration, and reducing inflammatory symptoms. In clinical trials, it is used in combination with the FOLFOX chemotherapy regimen to improve treatment efficacy, enhance patient quality of life, and mitigate chemotherapy-induced toxicities, specifically by addressing neutrophil mitochondrial dysfunction. The drug is also known for its ability to stimulate lymphocyte activation and accelerate wound healing processes in other clinical contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium adenosine nucleonate.